Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
500 Additionally, PepGens PGN-EDO51, designed to skip exon 51 in the DMD gene, has shown promising results in Phase I clinical trials and is now in Phase II (NCT06079736)
//Cagrilintide Cagrilintide 1415456-99-3 1415456-99-3 5000 1g 2g 3g 2026-06-26 17653471880 [email protected] : Cagrilintide CAS 1415456-99-3 -20 98% CAS 1415456-99-3 Cagrilintide Pyr-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe- Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-OH(Disulfide bridgeCys2-Cys7) 98.0% / Cagrilintide -20 0.3% VIP 2026-08-04 42 VIP 2026-08-03 6000 1415456-99-3 VIP 2026-08-03 5000 VIP 2026-08-03 1415456-99-3 VIP 2026-08-03 100 /1415456-99-3/Cagrilintide/ VIP 2026-08-02 500 2026-08-02 1415456-99-3 VIP 2026-08-01 3300 1415456-99-3 Cagrilintide VIP 2026-07-31 4800 1415456-99-3Cagrilintide VIP 2026-07-31 100
3 COAs available 5mg / Lot 3548087 HPLC / Tested 5/27/2026 A New Standard for Peptide Manufacturing For research use only Step 01 Sourcing Raw peptide materials are sourced from FDA-registered, green-listed suppliers, then verified and third-party tested on receipt
KotoglouPKalaitzakisAVezyrakiPTzavarasTMichalisLKDantzerFet al
This compound is strictly intended for research use only (RUO) and is not approved for human medical or therapeutic use
US$ 21.30
US$ 25.81
US$ 21.16
US$ 29.08
US$ 23.74
US$ 28.05
